Financial Disclosure: Dr Johansen reports research support from NIDDK; personal fees from and advisory board participation for GSK and Vifor; also reports participation in an NIAID OSMB and a NIDDK DSMB as well as serving as an Associate Editor for JASN. Dr Chertow reports receiving fees from AstraZeneca for the DAPA-CKD trial steering committee, research grants from NIDDK and Amgen; board of directors for Satellite Healthcare; receiving fees for advisory boards from Baxter, Cricket, DiaMedica and Reata; receiving fees from Akebia, Sanifit and Vertex for trial steering committees, and receiving fees for data and safety monitoring board service from Angion, Bayer, and ReCor. Dr Israni reports receiving research funds/grants awarded to Hennepin Healthcare Research Institute from Gilead, Health Resources and Services Administration, NIH and AHRQ. He has served on an Advisory Board for CSL Behring; receives consulting fees from Medical Review Institute of America; and discloses family members that are employees of Vera and GSK pharmaceutical companies. Dr Ku reports grant support from Care DX, NIDDK, and Natera; received honorarium from New York Academy of Medicine; reports stock ownership in Edison company; received gifts made to UCSF to support research; and is a member of the AKF Kidney Health Equity Coalition as well as an Associate Editor for AJKD. Dr Obrador reports grant funding from Fundación Río Arronte, AstraZeneca, and Secretaría de Tecnología, Educación e Innovación de la CDMX; royalties from Elsevier Barcelona and UpTo Date/Wolters Kluwer; honoraria received from GlaxoSmithKline and AbbVie; travel support from GlaxoSmithKline, AstraZeneca, and KDIGO; advisory board participation for GlaxoSmithKline; receiving discounted medications from Novartis for SIPASA clinics; and serving on boards SIPASA (Pan American Health Care System), Fundación Mexicana del Rin~ón and Consejo Mexicano para la Acreditación de la Educación Médica in unpaid roles. Dr O’Hare reports institutional funding from VA HSR&D; honoraria and travel support from UCSF Division of Nephrology; advisory board for Murea; and travel fees from NKF Northern California and JAMA. Dr Roetker reports institutional research grants from Merck & Co. and NIH. Dr Scherer reports royalties from UpToDate; consulting fees from Vifor/Cara Pharmaceuticals; and member of the clinical advisory board for Monogram Health. Dr St. Peter reports grant support from NIH and the University of Minnesota Office of Discovery and Translation; serving as Director for Advancing Kidney Health through Optimal Medication Management Initiative, personal fees from Total Renal Care, Inc; and medical writing from Bayer. Dr Snyder reports research funding from Health Resources and Services Administration, US Department of Health and Human Services; honorarium from Houston Methodist and American Foundation for Donation and Transplantation; participation in DSMB for A Multicenter Randomized Placebo-Controlled Trial of Intravenous Thyroxine for Heart-Eligible BD Organ Donors; editor for AJT and Transplantation journals; and membership in the Board of Directors for Donate Life America, LifeSource, and Organ Donation and Transplantation Alliance. Dr Winkelmayer reports grants/contracts from NIH and Health Care Service Corporation; honoraria from Pharmacosmos; consulting fees from Relypsa and Unicycive; serving on advisory boards for Akebia, Ardelyx, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Merck & Co., Otsuka, Reata, Zydus; and travel support and co-chair for KDIGO committee. Dr Wong reports research funding from Doris Duke Charitable Foundation, NIH and National Palliative Care Research Center; and meeting/travel support from the National Kidney Foundation. Dr Wetmore reports institutional support from Amgen, BMS-Pfizer, GSK, Merck & Co, Genentech, OPKO, Relypsa, AstraZeneca, Acadia, and NIDDK; Dr Wetmore also reports payments from Vifor for presentations; participation in DSMB for CARSK and Vifor and advisory board for Aurinia and BMS-Pfizer Alliance. The remaining authors declare that they have no relevant financial interests.